About

Publications While At HealthPartners

selected publications

Journal Article

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. 

Lancet Oncology. 2016

Contact

full name

D. P. Carbone

Quick Info

 

Collaboration

Co-author network

Map of science